Effects of stellate ganglion block on cardiac coronary circulation

I Sasaki1, T Kaneko, N Iwatsuki

  • 1Department of Anesthesiology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aoba-ku, 980, Sendai, Japan.

Journal of Anesthesia
|July 11, 2013
PubMed

Insights

Stellate ganglion block (SGB) can negatively impact cardiac hemodynamics, reducing coronary blood flow and myocardial oxygen supply. However, inhaling 100% oxygen can counteract these adverse effects.

Area of Science:

  • Cardiovascular Physiology
  • Autonomic Nervous System
  • Anesthesiology

Background:

  • The stellate ganglion plays a role in cardiac sympathetic innervation.
  • Stellate ganglion block (SGB) is used clinically, but its effects on cardiac hemodynamics require further investigation.

Purpose of the Study:

  • To investigate the influence of stellate ganglion block (SGB) on cardiac and coronary hemodynamics.
  • To assess the impact of SGB on myocardial oxygen supply and demand.

Main Methods:

  • Measurements of heart rate, coronary blood flow, left ventricular pressure, cardiac output, myocardial oxygen consumption, and myocardial oxygen extraction ratio were performed in nine dogs.
  • SGB was induced using 2 ml of 1% mepivacaine injection.

Main Results:

  • Left SGB decreased coronary blood flow (CBF) by 10% and left ventricular pressure increase rate (LV max dP/dt) by 15%.
  • Right SGB decreased CBF by 30%, LV max dP/dt by 25%, heart rate (HR) by 20%, cardiac output (CO) by 15%, and myocardial oxygen consumption (MVO2) by 25%.
  • SGB on either side increased myocardial oxygen extraction ratio (MOER), indicating a relative deficit in CBF, which was reversed by 100% oxygen inhalation.

Conclusions:

  • Stellate ganglion block can impair the myocardial oxygen supply-demand relationship.
  • The negative effects of SGB on myocardial oxygenation can be mitigated by 100% oxygen administration.

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...